Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T77431
|
||||
Target Name |
5-HT 3 receptor
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Anxiety disorder [ICD9: 300, 311; ICD10: F32, F40-F42] | ||||
Chronic functional vomiting [ICD9: 536.2; ICD10: R11.10] | |||||
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3] | |||||
Gastro-oesophageal reflux [ICD9: 530; ICD10: K21] | |||||
Gastric motility disorder [ICD10: K22.4] | |||||
Generalized anxiety disorder; Major depressive disorder [ICD9:300, 300.02, 311, 296.2, 296.3, 710.0; ICD10: F32, F40-F42, F41.1, F33, M32] | |||||
Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10: A09, K58, K59.1] | |||||
Mood disorder [ICD10: F30-F39] | |||||
Nausea [ICD10: R11] | |||||
Substance dependence [ICD10: F10-F19] | |||||
Unspecified [ICD code not available] | |||||
BioChemical Class |
Channels/Pores (TC=1)
|
||||
Drugs and Mode of Action | |||||
Drug(s) | LITOXETINE | Drug Info | Phase 3 | Mood disorder | [544832] |
Renzapride | Drug Info | Phase 3 | Irritable bowel syndrome | [536224], [539568] | |
ZATOSETRON MALEATE | Drug Info | Phase 3 | Anxiety disorder | [551821] | |
DDP-225 | Drug Info | Phase 2 | Irritable bowel syndrome | [536224] | |
Lintopride | Drug Info | Phase 2 | Nausea | [534100] | |
Pumosetrag | Drug Info | Phase 2 | Irritable bowel syndrome | [536224] | |
BIMU-1 | Drug Info | Phase 1 | Cognitive disorders | [533870], [539484] | |
ITASETRON | Drug Info | Phase 1 | Nausea | [524948] | |
Pumosetrag | Drug Info | Phase 1 | Gastro-oesophageal reflux | [536224] | |
Tedatioxetine | Drug Info | Phase 1 | Generalized anxiety disorder; Major depressive disorder | [548243] | |
BRL-46470 | Drug Info | Discontinued in Phase 2 | Anxiety disorder | [539455], [544854] | |
DDP-225 | Drug Info | Discontinued in Phase 2 | Chronic functional vomiting | [536224] | |
E-3620 | Drug Info | Discontinued in Phase 2 | Gastric motility disorder | [545633] | |
Fabesetron | Drug Info | Discontinued in Phase 2 | Irritable bowel syndrome | [544894] | |
WAY-100289 | Drug Info | Discontinued in Phase 1 | Anxiety disorder | [544921] | |
CR-3124 | Drug Info | Terminated | Substance dependence | [548288] | |
Modulator | (R)-zacopride | Drug Info | |||
BIMU-1 | Drug Info | [533870] | |||
BRL-46470 | Drug Info | ||||
CR-3124 | Drug Info | ||||
DDP-225 | Drug Info | [1572591] | |||
E-3620 | Drug Info | [1572591] | |||
Fabesetron | Drug Info | ||||
ITASETRON | Drug Info | [1572591] | |||
Lintopride | Drug Info | [534100] | |||
LITOXETINE | Drug Info | ||||
Pumosetrag | Drug Info | ||||
Renzapride | Drug Info | ||||
S-21007 | Drug Info | ||||
SC-52491 | Drug Info | ||||
SC-54750 | Drug Info | ||||
Tedatioxetine | Drug Info | [1572591] | |||
WAY-100289 | Drug Info | [533730] | |||
ZATOSETRON MALEATE | Drug Info | ||||
References | |||||
Ref 524948 | ClinicalTrials.gov (NCT02259985) Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects. U.S. National Institutes of Health. | ||||
Ref 533870 | Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45. | ||||
Ref 534100 | The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9. | ||||
Ref 536224 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | ||||
Ref 539455 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2302). | ||||
Ref 539484 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 234). | ||||
Ref 539568 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 244). | ||||
Ref 544832 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001264) | ||||
Ref 544854 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001328) | ||||
Ref 544894 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001434) | ||||
Ref 544921 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001552) | ||||
Ref 545633 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004004) | ||||
Ref 548243 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023694) | ||||
Ref 533730 | The selective 5-HT3 receptor antagonist, WAY100289, enhances spatial memory in rats with ibotenate lesions of the forebrain cholinergic projection system. Psychopharmacology (Berl). 1995 Feb;117(3):318-32. | ||||
Ref 533870 | Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.